Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2015. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMR) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider share acquisitions rather than a financial performance report.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details specific share acquisition events on October 9, 2015, executed through GSK's ShareReward Plan at a price of 1307.31 pence per Ordinary Share.
Management Commentary and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly lists the acquisition of shares by the following individuals:
- Sir Andrew Witty: 10 shares (personal) and 10 shares (matching)
- Mr R G Connor: 10 shares (personal) and 10 shares (matching)
- Mr S Dingemans: 10 shares (personal) and 10 shares (matching)
- Mr N Hirons: 9 shares (personal) and 9 shares (matching)
- Mr D S Redfern: 10 shares (personal) and 10 shares (matching)
- Ms C Thomas: 10 shares (personal) and 10 shares (matching)
- Mr P C Thomson: 10 shares (personal) and 10 shares (matching)
- Dr P J T Vallance: 9 shares (personal) and 9 shares (matching)
- Ms E Walmsley: 9 shares (personal) and 9 shares (matching)
- Mrs V A Whyte: 10 shares (personal) and 10 shares (matching)
Investor Verification Checklist
- Verify the total number of shares acquired by each Director/PDMR under the ShareReward Plan.
- Confirm the transaction date of October 9, 2015, and the execution price of 1307.31 pence per share.
- Review the company's annual Form 20-F for comprehensive financial data, as this 6-K does not contain financial statements.